OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
Lorlatinib
24 minutes
Posted Nov 6, 2018 at 6:24 pm.
0:00
24:13
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Reviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?
Previous
October '18 Updates
Next
Cyclophosphamide
← See all 273 episodes of OncoPharm